Literature DB >> 709510

The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation.

J P Minton, E W Martin.   

Abstract

The concept of second-look surgery was introduced by Wangensteen 25 years ago, and 17% of patients were reported to be converted to a cancer-free state. Instead of an arbitrary time interval for reoperation, serial CEA values were used as the indicator of colon cancer recurrence and second-look operation. Twenty-two retrospective and 18 prospective patients were evaluable. There was no operative mortality. The CEA Nomogram was used to determine whether the CEA change was significant. All patient-samples were analyzed in duplicate, stored, and compared with the most recent sample; therefore, each patient served as his own control. The prospective results emphasize the importance of minimizing the time delay between a significant change in CEA values and reoperation. Equally important are the frequency of serial determinations (every one or two months), a thorough understanding of the limitations of the CEA radioimmunoassay, and the clinical condition of the patient.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709510     DOI: 10.1002/1097-0142(197809)42:3+<1422::aid-cncr2820420807>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Routine compared with nonscheduled follow-up of patients with "curative" surgery for colorectal cancer.

Authors:  R Bergamaschi; J P Arnaud
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

2.  The usefulness and limitations of CEA assay in the management of colorectal cancer.

Authors:  H Tomoda; M Furusawa
Journal:  Jpn J Surg       Date:  1981-01

3.  CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols.

Authors:  G Steele; S Ellenberg; K Ramming; M O'Connell; C Moertel; H Lessner; H Bruckner; J Horton; P Schein; N Zamcheck; J Novak; E D Holyoke
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

4.  Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.

Authors:  K R Hine; P W Dykes
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

5.  Carcinoembryonic antigen: physician attitudes, patterns of use, and impact upon patient care.

Authors:  S L Vest; J K Roche
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

6.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.

Authors:  K Sakamoto; Y Haga; R Yoshimura; H Egami; Y Yokoyama; M Akagi
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

7.  Hepatic resection for metastatic cancer.

Authors:  W J Kortz; W C Meyers; J B Hanks; B D Schirmer; R S Jones
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

8.  Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer.

Authors:  K A Chester; R H Begent
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

Review 9.  Follow-up plans after treatment of primary colon and rectum cancer.

Authors:  G Steele
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

10.  [Effect of serial CEA determination on diagnosis, therapy and prognosis of recurrent colorectal cancer].

Authors:  B Mentges
Journal:  Langenbecks Arch Chir       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.